Literature DB >> 15366974

Data quality management in pharmacovigilance.

Marie Lindquist1.   

Abstract

Pharmacovigilance relies on information gathered from the collection of individual case safety reports and other pharmacoepidemiological data. Even given the inherent limitations of spontaneous reports, the usefulness of this data source can be improved with good data quality management. Although under-reporting cannot be remedied this way, the negative impact of incomplete reports, which is another serious problem in pharmacovigilance, can be reduced. Quality management consists of quality planning, quality control, quality assurance and quality improvements. The pharmacovigilance data processing cycle starts with data collection and, in computerised systems, data entry; the next step is data storage and maintenance; followed by data selection, retrieval and manipulation. The resulting data output is analysed and assessed. Finally, conclusions are drawn and decisions made. The increased knowledge feeds back into the data processing cycle. Focussing on the first three steps of the data processing cycle, the different quality dimensions associated with these steps are described in this review, together with examples relevant to pharmacovigilance data. Functioning, well documented, and transparent quality management systems will benefit not only those involved in data collection, management and output production, but, ultimately, also the pharmacovigilance end users, the patients.

Entities:  

Mesh:

Year:  2004        PMID: 15366974     DOI: 10.2165/00002018-200427120-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.228


  25 in total

1.  A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database.

Authors:  M Lindquist; M Ståhl; A Bate; I R Edwards; R H Meyboom
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

2.  Spontaneous ADR reporting and drug safety signal induction in perspective. To honour Professor Jens Schou.

Authors:  I R Edwards
Journal:  Pharmacol Toxicol       Date:  2000

Review 3.  Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA).

Authors:  Elliot G Brown
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

5.  Concepts in risk-benefit assessment. A simple merit analysis of a medicine?

Authors:  R Edwards; B E Wiholm; C Martinez
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

6.  Reporting of adverse drug reactions by hospital doctors and the response to intervention.

Authors:  P McGettigan; J Golden; R M Conroy; N Arthur; J Feely
Journal:  Br J Clin Pharmacol       Date:  1997-07       Impact factor: 4.335

7.  Record linkage studies for postmarketing drug surveillance: data quality and validity considerations.

Authors:  A S Stergachis
Journal:  Drug Intell Clin Pharm       Date:  1988-02

8.  International pharmacovigilance: developing cooperation to meet the challenges of the 21st century.

Authors:  M M Lumpkin
Journal:  Pharmacol Toxicol       Date:  2000

9.  A population based case-cohort study of drug-induced anaphylaxis.

Authors:  M M van der Klauw; B H Stricker; R M Herings; W S Cost; H A Valkenburg; J H Wilson
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

10.  Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994.

Authors:  M D Rawlins
Journal:  J R Coll Physicians Lond       Date:  1995 Jan-Feb
View more
  20 in total

1.  Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009.

Authors:  Jindrich Srba; Veronika Descikova; Jiri Vlcek
Journal:  Eur J Clin Pharmacol       Date:  2012-02-01       Impact factor: 2.953

2.  Pharmacovigilance is... Vigilance.

Authors:  I Ralph Edwards; Rachida Soulayamani Bencheikh
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

3.  Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.

Authors:  Carmen Ferrajolo; Annalisa Capuano; Katia M C Verhamme; Martijn Schuemie; Francesco Rossi; Bruno H Stricker; Miriam C J M Sturkenboom
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

4.  Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis.

Authors:  Irma Convertino; Stefano Salvadori; Alessandro Pecori; Maria Teresa Galiulo; Sara Ferraro; Maria Parrilli; Tiberio Corona; Giuseppe Turchetti; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

5.  Non-medical prescribers and pharmacovigilance: participation, competence and future needs.

Authors:  Derek Stewart; Katie MacLure; Vibhu Paudyal; Carmel Hughes; Molly Courtenay; James McLay
Journal:  Int J Clin Pharm       Date:  2013-01-01

6.  Community pharmacists' knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia.

Authors:  Tahir M Khan
Journal:  Ther Adv Drug Saf       Date:  2013-04

7.  Performance of probabilistic method to detect duplicate individual case safety reports.

Authors:  Philip Michael Tregunno; Dorthe Bech Fink; Cristina Fernandez-Fernandez; Edurne Lázaro-Bengoa; G Niklas Norén
Journal:  Drug Saf       Date:  2014-04       Impact factor: 5.606

8.  Development of a quality instrument for assessing the spontaneous reports of ADR/ADE using Delphi method in China.

Authors:  Lixun Chen; Ling Jiang; Aizong Shen; Wei Wei
Journal:  Eur J Clin Pharmacol       Date:  2016-06-16       Impact factor: 2.953

9.  Rheum rhaponticum Extract (ERr 731): Postmarketing Data on Safety Surveillance and Consumer Complaints.

Authors:  Jyh-Lurn Chang; Michael B Montalto; Peter W Heger; Eva Thiemann; Reinhard Rettenberger; Jürgen Wacker
Journal:  Integr Med (Encinitas)       Date:  2016-06

Review 10.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.